Pier Capital’s Heron Therapeutics HRTX Stock Holding History

Pier Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-326,574	Closed	-$7.67M	–	116
2019 Q4	$7.67M	Buy	326,574 +56,185	+21%	+$1.24M	1.25%	28
2019 Q3	$5M	Buy	270,389 +9,899	+4%	+$182K	0.85%	69
2019 Q2	$4.84M	Sell	260,490 -9,024	-3%	-$180K	0.75%	81
2019 Q1	$6.59M	Buy	269,514 +15,914	+6%	+$417K	1.02%	63
2018 Q4	$6.58M	Sell	253,600 -8,370	-3%	-$230K	1.31%	11
2018 Q3	$8.29M	Buy	+261,970	New	+$9.76M	1.05%	49

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Pier Capital's HRTX Position: Q1 2020 in Review

Pier Capital sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 326,574 shares — an estimated $7.67M sold.

Pier Capital first reported a position in HRTX in Q3 2018 and held it in 6 quarters. The position peaked at $8.29M in Q3 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Pier Capital reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Pier Capital sold 326,574 Heron Therapeutics shares in Q1 2020, an estimated $7.67M.
Pier Capital first reported a position in Heron Therapeutics in Q3 2018 and held it in 6 quarters.
Pier Capital's Heron Therapeutics position peaked at $8.29M in Q3 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Pier Capital's 13F filing for Q1 2020, filed 15 May 2020.